Cutaneous pharmacokinetics of escalating Ruxolitinib formulation doses utilizing a coherent Raman imaging pipeline

Systemic drug delivery for dermatological conditions yields little drug to the intended site of action resulting in adverse effects. Topical drug delivery is a viable alternative yet the local cutaneous pharmacokinetics (cPK) is relatively under-explored. Product dosing is dependent upon the knowledge of the dose-cPK relationship, which coincides with the pharmacodynamic (PD) activity. Coherent Raman imaging (CRI) can quantify tissue-specific drug localization and elucidate micro-scale cPK estimates, affording a clinically relevant cPK-PD relationship. This demonstration of a dose-cPK relationship utilizing CRI offers a stepping stone for additional formulation evaluation ex vivo.